frontiers | Frontiers in Pharmacology

TYPE Correction
PUBLISHED 20 January 2026
DOI 10.3389/fphar.2025.1758996

OPEN ACCESS

EDITED AND REVIEWED BY
Javier Echeverria,
University of Santiago, Chile

*CORRESPONDENCE
Francisney Pinto Nascimento,
francisney.nascimento@unila.edu.br

†These authors have contributed equally to this work

RECEIVED 02 December 2025
ACCEPTED 22 December 2025
PUBLISHED 20 January 2026

CITATION
Griebeler NM, Penayo Cremonese R, Correa YRF, Pereira PRM, Rial AF, Leite E, Gonçalves MVL, das Almas LRM, Cardoso NB, Cezar-dos-Santos F, Toci AT, Le-Quesne AM and Nascimento FP (2026) Correction: Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment.
Front. Pharmacol. 16:1758996.
doi: 10.3389/fphar.2025.1758996

Correction: Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment

Neide Maria Griebeler[1†], Ricardo Penayo Cremonese[1†], Yasmin Rafaela Fakih Correa[1], Priscila Romero Mazzini Pereira[1], Amanda Furjan Rial[2], Emanuela Leite[1], Maria Victoria Luz Gonçalves[1], Luiz Renato Marques das Almas[3], Nedice Borges Cardoso[4], Fernando Cezar-dos-Santos[1], Aline Theodoro Toci[4], Andrés Mojoli Le-Quesne[1] and Francisney Pinto Nascimento[1*]

[1]Laboratory of Cannabis and Psychedelics - LCP, Universidade Federal da Integração Latino Americana (UNILA), Foz do Iguaçu, Brazil, [2]POP-VET Veterinary Hospital, Foz do Iguaçu, Brazil, [3]Associação Santa Cannabis, Florianópolis, Brazil, [4]Environmental and Food Interdisciplinary Studies Laboratory - LEIMAA, Universidade Federal da Integração Latino Americana (UNILA), Foz do Iguaçu, Brazil

KEYWORDS
adverse events, cannabinoids, canine, efficacy, osteoarthritis, quality of life, safety

A Correction on
Cannabis-based extract for managing pain in dogs with osteoarthritis: efficacy and safety assessment

by Griebeler NM, Cremonese RP, Fakih Correa YR, Pereira PRM, Rial AF, Leite E, Gonçalves MVL, Marques das Almas LR, Cardoso NB, Cezar-dos-Santos F, Toci AT, Mojoli Le-Quesne A and Nascimento FP (2025). Front. Pharmacol. 16:1539704. doi: 10.3389/fphar.2025.1539704

The figure captions were in the wrong order in the PDF/HTML version of this paper. Figure 1 had the caption of Figure 2; Figure 2 had the caption of Figure 1; Figure 3 had the caption of Figure 6; Figure 4 had the caption of Figure 3. The order has now been corrected.

Furthermore, there was a mistake in the caption of Figure 5 as published. Figure 5 had the caption of Figure 6. The corrected caption of Figure 5 appears below.

There was also a mistake in the caption of Figure 6 as published. Figure 6 had the caption of Figure 3. The corrected caption of Figure 6 appears below.

The original article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.



FIGURE 1
Cannabinoids present in the extract provided by the Santa Cannabis Association.



FIGURE 2
Flowchart of patient triage. This image summarizes the animal selection and study methodology over 90 days, representing the excluded animals and treatment groups.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.



FIGURE 3
Graphical representation of HCPI and CBPI outcomes.



FIGURE 4
Graphical summary of veterinary clinical assessment outcomes.



FIGURE 5
Biochemical marker levels during the 90-day treatment period. Part I. *p < 0.05 for significant differences between cannabis oil and placebo groups. **(A)** p < 0.05 for significant differences between time points 0 and 30 within the placebo group. **(B)** P < 0.05 for significant differences between time points 0 and 30 within the cannabis oil group. **(C)** p < 0.05 for significant differences between time points 0 and 90 within the cannabis oil group. **(D)** p < 0.05 for significant differences between time points 30 and 90 within the cannabis oil group. **(E)** p < 0.05 for significant differences between time points 30 and 90 within the placebo group.



FIGURE 6
Biochemical marker levels during the 90-day treatment period. Part II.*p < 0.05 for significant differences between cannabis oil and placebo groups. **(A)** P < 0.05 for significant differences between time points 0 and 30 with in the placebo group. **(B)** P < 0.05 for significant differences between time points 0 and 30 with in the cannabis oil group. **(C)** P < 0.05 for significant differences between time points 0 and 90 with in the cannabis oil group. **(D)** P < 0.05 for Q27 significant differences between time points 30 and 90 with in the cannabis oilgroup. **(E)** P < 0.05 for significant differences between time points 30 and 90 with in the placebo group.